Clinical trial NCT00281502 - References

Hepatitis C — The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy

Citation(s)

•   Amodio P, Del Piccolo F, Marchetti P, Angeli P, Iemmolo R, Caregaro L, Merkel C, Gerunda G, Gatta A
  Clinical features and survivial of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. Hepatology. 1999 Jun;29(6):1662-7.
•   Arguedas MR, DeLawrence TG, McGuire BM
  Influence of hepatic encephalopathy on health-related quality of life in patients with cirrhosis. Dig Dis Sci. 2003 Aug;48(8):1622-6.
•   Bustamante J, Rimola A, Ventura PJ, Navasa M, Cirera I, Reggiardo V, Rodés J
  Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol. 1999 May;30(5):890-5.
•   Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT
  Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002 Mar;35(3):716-21.
•   Groeneweg M, Moerland W, Quero JC, Hop WC, Krabbe PF, Schalm SW
  Screening of subclinical hepatic encephalopathy. J Hepatol. 2000 May;32(5):748-53.
•   Groeneweg M, Quero JC, De Bruijn I, Hartmann IJ, Essink-bot ML, Hop WC, Schalm SW
  Subclinical hepatic encephalopathy impairs daily functioning. Hepatology. 1998 Jul;28(1):45-9.

The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy. Phase A: Breath Testing and Colonic Transit in Hepatic Encephalopathy. Phase B: A Randomized Double Blind, Placebo Controlled Trial of Rifaximin for Hepatic Encephalopathy

Details for clinical trial NCT00281502